Azenta/$AZTA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Azenta

Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.

Ticker

$AZTA
Sector
Primary listing

Employees

3,000

Azenta Metrics

BasicAdvanced
$1.4B
-
-$2.41
1.65
-

What the Analysts think about Azenta

Analyst ratings (Buy, Hold, Sell) for Azenta stock.

Bulls say / Bears say

Adjusted EBITDA margin increased by 260 basis points to 12.3% in Q3, reflecting effective cost controls and operational efficiency. (Reuters)
Q3 revenue in the Multiomics segment rose 4% year-over-year, fueled by strong demand for Next-Generation Sequencing services, underscoring the strength of high-margin offerings. (Reuters)
Management reaffirmed its full-year organic revenue growth target of 3–5% and projected a 300 basis point increase in adjusted EBITDA margin, demonstrating confidence in continued growth and profitability. (Reuters)
Q3 revenue remained flat at $144 million, falling about 3.6% short of analyst expectations, pointing to stalled revenue growth. (Reuters)
Sample Management Solutions revenue dropped 4% year-over-year in Q3, showing continued softness in core cold-chain lines. (Reuters)
Wall Street’s median 12-month price target stands at $32.50, just 0.3% above the latest closing price, with analysts maintaining a consensus “hold” rating, suggesting minimal conviction and upside. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.

Azenta Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Azenta Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AZTA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs